课题基金 / 基金详情

MODULATION OF IFN ACTION VIA NOVEL REGULATORY FACTORS

MODULATION OF IFN ACTION VIA NOVEL REGULATORY FACTORS
通过新的调控因子调节干扰素的作用
批准号:
6513253
负责人:
DHAN V. KALVAKOLANU
金额:
$36.47万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-16 至 2004-06-30

项目摘要

项目成果

DHAN V. KALVAKOLANU的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Interferons (IFN) are a family of multifunctional cytokines that modulate the cellular antitumor, antiviral and immune responses. They are in clinical use for the therapy of human cancers. IFN actions are mediated by IFN stimulated gene (ISG) products. A number of transcription factors are activated though the Janus Kinase-Signal Transducing Activators of Transcription (JAK-STAT) pathway upon stimulation cells with IFNs. Among these is a burgeoning class of transcription factors called the IFN regulatory factors (IRF) which exhibit homology to oncoprotein myb in their DNA binding domains. IRFs are essential for the prevention of leukemia, regulation of apoptosis, cell cycle control and lymphocyte maturation. P48, an IRF family member, is a DNA binding factor which in association with STAT proteins inhibits tumor growth in IFN-treated cells. IFN-gamma enhances biological responses to IFN-alpha/beta through an increase in p48 gene expression in several cells. In cells transformed by dominant viral oncogenes, IFN responses are inhibited because of repression of p48 gene. The gene encoding p48 is modulated in a unique manner by IFN-gamma because it possesses a novel IFN-gamma response element which does not bind known IFN-regulated factors. Based on our preliminary studies we hypothesize that IFN-gamma modulated expression of p48 is mediated novel factors. We now propose to isolate and characterize the genes encoding these factors and determine their role in cell growth inhibition. Preliminary studies indicate that these factors are distinct but are related to families of regulatory factors involved in cell growth function and prevention of tumor growth. It is likely that mutations in these gene products may contribute to resistance to IFN-therapy. Based on such observations we predict that these factors may be essential not only for regulating IFN-action but also for homeostasis of host defenses. We believe that loss of genes encoding these factors may be linked to human cancers. Thus they may serve as markers for monitoring mutations leading to such diseases. These genes may be useful for genetic therapy of cancer, if such mutated genes are discovered. Therefore, it is important to characterize the actions of these novel factors and their role in growth control.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GRIM19 for head and neck cancer therapy
  • 批准号:
    9408784
  • 项目类别:
  • 资助金额:
    $29.85万
  • 财政年份:
    2017
  • 负责人:
    DHAN V. KALVAKOLANU
  • 依托单位:
Cytokine modulated novel growth inhibitory mechanisms
  • 批准号:
    7406846
  • 项目类别:
  • 资助金额:
    $25.98万
  • 财政年份:
    2004
  • 负责人:
    DHAN V. KALVAKOLANU
  • 依托单位:
Cytokine modulated model growth inhibitory mechanisms
  • 批准号:
    8257946
  • 项目类别:
  • 资助金额:
    $26.18万
  • 财政年份:
    2004
  • 负责人:
    DHAN V. KALVAKOLANU
  • 依托单位:
Cytokine modulated model growth inhibitory mechanisms
  • 批准号:
    7840509
  • 项目类别:
  • 资助金额:
    $26.97万
  • 财政年份:
    2004
  • 负责人:
    DHAN V. KALVAKOLANU
  • 依托单位:
海外基金